CR20190301A - Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer - Google Patents
Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncerInfo
- Publication number
- CR20190301A CR20190301A CR20190301A CR20190301A CR20190301A CR 20190301 A CR20190301 A CR 20190301A CR 20190301 A CR20190301 A CR 20190301A CR 20190301 A CR20190301 A CR 20190301A CR 20190301 A CR20190301 A CR 20190301A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- salts
- methods
- dna
- mediated disease
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 5
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical class NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 13
- 150000003839 salts Chemical class 0.000 abstract 13
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000000543 intermediate Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La memoria descriptiva se refiere en general a compuestos de Fórmula (I):y sales farmacéuticamente aceptables de los mismos, donde R1 y R2 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir una enfermedad mediada por PC-ADN, incluyendo el cáncer. La memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales; kits que comprenden tales compuestos y sales; métodos de fabricación de dichos compuestos y sales; intermedios útiles en la fabricación de dichos compuestos y sales; y a los métodos para tratar una enfermedad mediada por PC-ADN, incluyendo el cáncer, usando dichos compuestos y sales.The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436619P | 2016-12-20 | 2016-12-20 | |
| PCT/EP2017/083625 WO2018114999A1 (en) | 2016-12-20 | 2017-12-19 | Amino-triazolopyridine compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190301A true CR20190301A (es) | 2019-09-04 |
Family
ID=60937727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190301A CR20190301A (es) | 2016-12-20 | 2017-12-19 | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10407446B2 (es) |
| EP (1) | EP3558997B1 (es) |
| JP (1) | JP6883653B2 (es) |
| KR (1) | KR102220971B1 (es) |
| CN (1) | CN110177791B (es) |
| AR (1) | AR110400A1 (es) |
| AU (1) | AU2017384388B2 (es) |
| BR (1) | BR112019012217B1 (es) |
| CA (1) | CA3046339C (es) |
| CL (1) | CL2019001714A1 (es) |
| CO (1) | CO2019007810A2 (es) |
| CR (1) | CR20190301A (es) |
| CY (1) | CY1124239T1 (es) |
| DK (1) | DK3558997T3 (es) |
| DO (1) | DOP2019000168A (es) |
| EA (1) | EA037745B1 (es) |
| EC (1) | ECSP19044159A (es) |
| ES (1) | ES2867274T3 (es) |
| HR (1) | HRP20210548T1 (es) |
| HU (1) | HUE054548T2 (es) |
| IL (1) | IL267158B (es) |
| JO (1) | JOP20190151B1 (es) |
| LT (1) | LT3558997T (es) |
| MA (1) | MA47079B1 (es) |
| MX (1) | MX390535B (es) |
| MY (1) | MY183036A (es) |
| NI (1) | NI201900062A (es) |
| NZ (1) | NZ755222A (es) |
| PE (1) | PE20191474A1 (es) |
| PH (1) | PH12019501350B1 (es) |
| PL (1) | PL3558997T3 (es) |
| PT (1) | PT3558997T (es) |
| RS (1) | RS61701B1 (es) |
| SI (1) | SI3558997T1 (es) |
| SM (1) | SMT202100225T1 (es) |
| TW (1) | TWI776835B (es) |
| UA (1) | UA123032C2 (es) |
| WO (1) | WO2018114999A1 (es) |
| ZA (1) | ZA201904695B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6883653B2 (ja) | 2016-12-20 | 2021-06-09 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用 |
| TWI820146B (zh) | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| WO2020186211A1 (en) * | 2019-03-13 | 2020-09-17 | The Uab Research Foundation | Methods and compositions for treating polyoma virus infection |
| TWI899080B (zh) * | 2019-05-27 | 2025-10-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｄｎａ依賴性蛋白激酶抑制劑 |
| EP3983542A2 (en) | 2019-06-17 | 2022-04-20 | CRISPR Therapeutics AG | Methods and compositions for improved homology directed repair |
| US20230055321A1 (en) * | 2019-11-22 | 2023-02-23 | Medshine Discovery Inc. | Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors |
| TWI807228B (zh) * | 2019-11-25 | 2023-07-01 | 大陸商南京明德新藥研發有限公司 | 作為dna-pk抑制劑的嘧啶并吡咯類化合物 |
| AU2020391487B2 (en) * | 2019-11-26 | 2026-04-23 | Primmune Therapeutics, Inc. | TLR7 agonists |
| CN113121538B (zh) * | 2019-12-31 | 2023-04-21 | 成都百裕制药股份有限公司 | 呋喃衍生物及其在医药上的应用 |
| CN113121574B (zh) * | 2019-12-31 | 2023-02-17 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的用途 |
| WO2021136461A1 (zh) * | 2019-12-31 | 2021-07-08 | 成都百裕制药股份有限公司 | 嘌呤衍生物及其在医药上的应用 |
| CN113493471B (zh) * | 2020-04-03 | 2024-06-11 | 山东轩竹医药科技有限公司 | 杂芳环类激酶抑制剂 |
| AU2021256235B2 (en) * | 2020-04-17 | 2024-05-09 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Imidazolidinone derivatives and medical use thereof |
| WO2021213460A1 (zh) * | 2020-04-23 | 2021-10-28 | 山东轩竹医药科技有限公司 | 三并环类激酶抑制剂 |
| CA3181340A1 (en) | 2020-04-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
| WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
| WO2022017368A1 (zh) * | 2020-07-20 | 2022-01-27 | 首药控股(北京)股份有限公司 | Dna-pk选择性抑制剂及其制备方法和用途 |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| CN114249753A (zh) * | 2020-09-22 | 2022-03-29 | 山东轩竹医药科技有限公司 | 三唑并吡啶类激酶抑制剂 |
| AU2021346954A1 (en) * | 2020-09-24 | 2023-05-25 | Auckland Uniservices Limited | Novel aminopyridines and their use in treating cancer |
| CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
| CN114634522A (zh) * | 2020-12-15 | 2022-06-17 | 江苏恒瑞医药股份有限公司 | 嘌呤酮衍生物、其制备方法及其在医药上的应用 |
| WO2022133246A1 (en) | 2020-12-17 | 2022-06-23 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
| TW202241901A (zh) * | 2020-12-21 | 2022-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘌呤酮衍生物、其製備方法及其在醫藥上的應用 |
| CN114656487B (zh) * | 2020-12-22 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 稠合嘧啶类化合物、其制备方法及其在医药上的应用 |
| WO2022135555A1 (zh) * | 2020-12-24 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类化合物、其制备方法及其在医药上的应用 |
| CN116917288B (zh) * | 2021-03-22 | 2026-04-14 | 成都赜灵生物医药科技股份有限公司 | 一种7,9-二氢嘌呤衍生物及其制药用途 |
| IL307740A (en) | 2021-04-17 | 2023-12-01 | Intellia Therapeutics Inc | DNA-dependent protein kinase inhibitors and their compositions and uses |
| US20240254145A1 (en) * | 2021-05-19 | 2024-08-01 | Zai Lab (Shanghai) Co., Ltd. | Salt form and crystal form of heterocyclic substituted purinone derivative |
| CN117377676B (zh) * | 2021-06-29 | 2026-04-07 | 康百达（四川）生物医药科技有限公司 | 嘌呤衍生物的晶型及其药物组合物 |
| CN116023395B (zh) * | 2021-10-25 | 2025-07-15 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023394B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| CN116023393B (zh) * | 2021-10-25 | 2025-08-12 | 山东轩竹医药科技有限公司 | 三环类激酶抑制剂的晶型 |
| US20250305004A1 (en) * | 2022-05-13 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| KR20250116727A (ko) | 2022-12-06 | 2025-08-01 | 아스트라제네카 아베 | Polq 저해제 |
| CN121794270A (zh) * | 2023-07-21 | 2026-04-03 | 钟卫 | 取代的2-氨基-9-(3,3-二氟哌啶-4-基)-7,9-二氢-8h-嘌呤-8-酮化合物及其在癌症治疗中的用途 |
| WO2025049481A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025181336A1 (en) | 2024-03-01 | 2025-09-04 | Cellectis Sa | Compositions and methods for hbb-editing in hspc |
| TW202547478A (zh) | 2024-05-31 | 2025-12-16 | 瑞典商阿斯特捷利康公司 | Ｐｏｌｑ抑制劑 |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| CN1922141A (zh) | 2004-02-23 | 2007-02-28 | 大日本住友制药株式会社 | 新的杂环化合物 |
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20090023723A1 (en) | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| JP2009511528A (ja) | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群 |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| CA2691214A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
| JP5129812B2 (ja) | 2007-06-15 | 2013-01-30 | Ｍｓｄ株式会社 | ビシクロアニリン誘導体 |
| MX2010002115A (es) | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
| JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| CA2788678C (en) | 2010-02-03 | 2019-02-26 | Signal Pharmaceuticals, Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| UY34032A (es) | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| JP6121658B2 (ja) | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| PH12014500869A1 (en) | 2011-10-19 | 2014-06-30 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
| TWI664968B (zh) * | 2012-03-15 | 2019-07-11 | 標誌製藥公司 | 使用tor激酶抑制劑之癌症治療 |
| CN102675897B (zh) | 2012-05-18 | 2015-04-29 | 陕西师范大学 | 硫脲/脲芳胺染料及其制备方法和应用 |
| CN103864792B (zh) | 2012-12-12 | 2017-01-18 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮并环类化合物 |
| CA2902858A1 (en) | 2013-02-28 | 2014-09-04 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| NO2714752T3 (es) | 2014-05-08 | 2018-04-21 | ||
| JP6883653B2 (ja) | 2016-12-20 | 2021-06-09 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用 |
-
2017
- 2017-12-19 JP JP2019533052A patent/JP6883653B2/ja active Active
- 2017-12-19 WO PCT/EP2017/083625 patent/WO2018114999A1/en not_active Ceased
- 2017-12-19 MA MA47079A patent/MA47079B1/fr unknown
- 2017-12-19 ES ES17825829T patent/ES2867274T3/es active Active
- 2017-12-19 MY MYPI2019003492A patent/MY183036A/en unknown
- 2017-12-19 EA EA201991399A patent/EA037745B1/ru unknown
- 2017-12-19 CN CN201780078065.XA patent/CN110177791B/zh active Active
- 2017-12-19 UA UAA201907754A patent/UA123032C2/uk unknown
- 2017-12-19 AR ARP170103582A patent/AR110400A1/es active IP Right Grant
- 2017-12-19 PH PH1/2019/501350A patent/PH12019501350B1/en unknown
- 2017-12-19 RS RS20210447A patent/RS61701B1/sr unknown
- 2017-12-19 NZ NZ755222A patent/NZ755222A/en unknown
- 2017-12-19 BR BR112019012217-6A patent/BR112019012217B1/pt active IP Right Grant
- 2017-12-19 US US15/846,679 patent/US10407446B2/en active Active
- 2017-12-19 SM SM20210225T patent/SMT202100225T1/it unknown
- 2017-12-19 PT PT178258299T patent/PT3558997T/pt unknown
- 2017-12-19 PL PL17825829T patent/PL3558997T3/pl unknown
- 2017-12-19 CR CR20190301A patent/CR20190301A/es unknown
- 2017-12-19 HU HUE17825829A patent/HUE054548T2/hu unknown
- 2017-12-19 MX MX2019007189A patent/MX390535B/es unknown
- 2017-12-19 DK DK17825829.9T patent/DK3558997T3/da active
- 2017-12-19 PE PE2019001276A patent/PE20191474A1/es unknown
- 2017-12-19 SI SI201730707T patent/SI3558997T1/sl unknown
- 2017-12-19 LT LTEP17825829.9T patent/LT3558997T/lt unknown
- 2017-12-19 AU AU2017384388A patent/AU2017384388B2/en active Active
- 2017-12-19 HR HRP20210548TT patent/HRP20210548T1/hr unknown
- 2017-12-19 JO JOP/2019/0151A patent/JOP20190151B1/ar active
- 2017-12-19 EP EP17825829.9A patent/EP3558997B1/en active Active
- 2017-12-19 CA CA3046339A patent/CA3046339C/en active Active
- 2017-12-19 KR KR1020197021026A patent/KR102220971B1/ko active Active
- 2017-12-20 TW TW106144799A patent/TWI776835B/zh active
-
2019
- 2019-06-06 IL IL267158A patent/IL267158B/en active IP Right Grant
- 2019-06-17 DO DO2019000168A patent/DOP2019000168A/es unknown
- 2019-06-19 CL CL2019001714A patent/CL2019001714A1/es unknown
- 2019-06-20 EC ECSENADI201944159A patent/ECSP19044159A/es unknown
- 2019-06-20 NI NI201900062A patent/NI201900062A/es unknown
- 2019-07-17 ZA ZA2019/04695A patent/ZA201904695B/en unknown
- 2019-07-19 CO CONC2019/0007810A patent/CO2019007810A2/es unknown
- 2019-07-30 US US16/526,219 patent/US11136340B2/en active Active
-
2021
- 2021-04-27 CY CY20211100360T patent/CY1124239T1/el unknown
- 2021-08-27 US US17/459,049 patent/US11746118B2/en active Active
-
2023
- 2023-07-10 US US18/349,220 patent/US20240124492A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190301A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| CO2018010951A2 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer |